Industry Trend Analysis - Collaboration Creates Value For Halozyme And Alexion's Product Pipelines - 29 JAN 2018

BMI View: Halozyme Therapeutics ' partnership with Alexion represents continued execution of its strategy to expand collaborations of its Enhanze drug delivery technology to fund development of its oncology pipeline. Alexion will be able to utilise the technology to increase the bioavailability of its drug candidates and achieve its aim of effectively treating rare diseases.

Alexion Pharmaceuticals and Halozyme Therapeutics have entered a collaboration and licence agreement that enables Alexion to use Halozyme's Enhanze drug-delivery technology in the development of subcutaneous formulations for their portfolio of products. Under the terms of the agreement, Halozyme will receive an initial USD40mn with the potential to earn additional payments of up to USD160mn for each target developed, subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also receive mid-single digit royalties on sales of commercialised products.

Increasing Collaborations Highlights Value Halozyme's Technology

Key Collaborations Generating Revenue For R&D
Percentage Of Halozyme's Total Revenues From Select Company Collaborations, 2014-2016
Source: Halozyme Therapeutics, BMI

This article is part of our Corporate Financing week coverage. To access this article subscribe now or sign up for free trial